Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

2.710 USD -0.070 (-2.52%)
Official Closing Price Updated: 5:41 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Corvus Pharma Com

< Previous 1 2 3 4 Next >
Corvus Pharmaceuticals to Present Data on Refinement of the Adenosine Gene Signature and Ciforadenant in Renal Cell Cancer at the ASCO20 Virtual Scientific Program
From GlobeNewswire News Releases
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2020 Financial Results on April 30, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2019 Financial Results on March 5, 2020
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From GlobeNewswire News Releases
Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium
From GlobeNewswire News Releases
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium
From GlobeNewswire News Releases
Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1/1b Clinical Trial of CPI-818 at the 12th Annual T-Cell Lymphoma Forum
From GlobeNewswire News Releases
Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting
Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy 
From GlobeNewswire News Releases
Thinking about buying stock in Corvus Pharmaceuticals, Fitbit, Intel, Sprint, or Slack Technologies?
InvestorsObserver issues critical PriceWatch Alerts for CRVS, FIT, INTC, S, and WORK. 
From PR Newswire
Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American Society of Hematology (ASH) Annual Meeting
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019
Event will provide a review of updated CPI-006 data from Phase 1/1b study and data on adenosine gene signature in renal cell cancer with ciforadenant presented at SITC 2019 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
CPI-006 data to be presented in oral presentation and poster presentation 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference
From GlobeNewswire News Releases
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2019 Financial Results on August 1, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Company to Host ASCO Investor & Analyst Reception on Sunday, June 2, 2019 at 6:00 pm CT 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2019 Financial Results on May 9, 2019
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT 
From GlobeNewswire News Releases
New Research Coverage Highlights EMCOR Group, Reven Housing REIT, Communications, Marine Products, Corvus Pharmaceuticals, and Energy Focus — Consolidated Revenues, Company Growth, and Expectations fo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCOR Group, Inc.... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that... 
From GlobeNewswire News Releases
Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present Updated Biomarker and Clinical Data on Lead Development Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback